Sign up to save your podcasts
Or
Share Rucaparib 'Very Active' for High-Grade Ovarian Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Rucaparib 'Very Active' for High-Grade Ovarian Cancer
Dr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor.
View all episodes
By MedscapeDr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor.